4SC broadens shareholder based with €12M fund raising
This article was originally published in Scrip
4SC, the Munich-based biopharmaceutical company, was able to raise €12 million through the sale of 3.5 million shares at €3.40 in a private placement to institutional investors. The new funds, which will be used to finance existing clinical programmes, extend the company's financial runway from the end of 2011 to the end of 2012.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.